PriceTargets.com logo

Diaceutics - DXRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 215
  • Forecasted Upside: 35.22%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 159 As of 09/16/2026 11:01 AM ET
▼ -1 (-0.63%)

This chart shows the closing price for DXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Diaceutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXRX

Analyst Price Target is GBX 215
▲ +35.22% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Diaceutics in the last 3 months. The average price target is GBX 215, with a high forecast of GBX 215 and a low forecast of GBX 215. The average price target represents a 35.22% upside from the last price of GBX 159.

This chart shows the closing price for DXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Diaceutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2026Canaccord Genuity GroupReiterated RatingBuyGBX 215
6/4/2026Canaccord Genuity GroupBoost TargetBuyGBX 215 ➝ GBX 216
1/15/2026Shore Capital GroupBoost TargetBuyGBX 180 ➝ GBX 215
7/22/2025Canaccord Genuity GroupReiterated RatingBuyGBX 180
7/10/2025Royal Bank Of CanadaLower TargetOutperformGBX 195 ➝ GBX 185
12/5/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
9/17/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
8/20/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
5/21/2024Canaccord Genuity GroupReiterated RatingBuyGBX 150
3/21/2024Canaccord Genuity GroupReiterated RatingBuyGBX 150
9/26/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
7/25/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
6/5/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
4/17/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
(Data available from 9/16/2021 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Diaceutics logo
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Read More

Today's Range

Now: GBX 159
Low: 159
High: 163

50 Day Range

MA: GBX 143.22
Low: 127
High: 161.40

52 Week Range

Now: GBX 159
Low: 125
High: 180

Volume

42,095 shs

Average Volume

196,281 shs

Market Capitalization

£134.93 million

P/E Ratio

1,445.45

Dividend Yield

N/A

Beta

0.884

Frequently Asked Questions

What sell-side analysts currently cover shares of Diaceutics?

The following equities research analysts have issued reports on Diaceutics in the last year: Canaccord Genuity Group Inc., and Shore Capital Group Ltd.
View the latest analyst ratings for DXRX.

What is the current price target for Diaceutics?

0 Wall Street analysts have set twelve-month price targets for Diaceutics in the last year. Their average twelve-month price target is GBX 215, suggesting a possible upside of 35.2%. Canaccord Genuity Group Inc. has the highest price target set, predicting DXRX will reach GBX 215 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of GBX 215 for Diaceutics in the next year.
View the latest price targets for DXRX.

What is the current consensus analyst rating for Diaceutics?

Diaceutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXRX will outperform the market and that investors should add to their positions of Diaceutics.
View the latest ratings for DXRX.

What other companies compete with Diaceutics?

Other companies that are similar to Diaceutics include Integrated Diagnostics, Abingdon Health, genedrive, Yourgene Health and ANGLE. Learn More about companies similar to Diaceutics.